Last reviewed 2026-05-31 · How we verify

Protiofat (PROTIOFATE)

Phase 2 active Small molecule ✓ Verified May 2026

Protiofat (generic name: PROTIOFATE) is a protiofate drug. It is currently in Phase 2 development.

Protiofat works by interacting with a specific biological pathway to produce a therapeutic effect.

Protiofat is a small molecule. It is also known by the synonyms PROTIOFATE, PROTIOFATE, and PROTIOFATO.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PROTIOFATE
Drug class	protiofate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a complex machine with many moving parts. Protiofat is a small tool that fits into a specific part of the machine, helping it work more efficiently. This can lead to changes in how the cell behaves, which can be beneficial for treating certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Protiofat CI brief — competitive landscape report
Protiofat updates RSS · CI watch RSS

Frequently asked questions about Protiofat

What is Protiofat?

Protiofat (PROTIOFATE) is a protiofate drug.

How does Protiofat work?

Protiofat works by interacting with a specific biological pathway to produce a therapeutic effect.

What is the generic name of Protiofat?

PROTIOFATE is the generic (nonproprietary) name of Protiofat.

What drug class is Protiofat in?

Protiofat belongs to the protiofate class. See all protiofate drugs at /class/protiofate.

What development phase is Protiofat in?

Protiofat is in Phase 2.

Drug class: All protiofate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing